Current Report Filing (8-k)
June 03 2020 - 9:29AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 2, 2020
RELMADA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55347
|
|
45-5401931
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
880
Third Avenue, 12th Floor
New
York, NY
|
|
10022
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (646) 876-3459
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading Symbol
|
|
Name
of exchange on which registered
|
Common
stock, $0.001 par value per share
|
|
RLMD
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
note
Item 8.01.
Other Events
The
Company updated its corporate presentation, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
June 3, 2020
|
RELMADA
THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/
Sergio Traversa
|
|
Name:
|
Sergio
Traversa
|
|
Title:
|
Chief
Executive Officer
|
2
Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart
From Sep 2023 to Sep 2024